Imatinib mesylate is the first anti-cancer drug developed specifically to target the molecular defect that causes a particular type of cancer. (cancerresearch.org)
Phase II, open - label, single - arm trial of imatinib mesylate in patients with metastatic melanoma harboring c - Kit mutation or amplification. (cancernetwork.com)
MADISON, N.J. — Feb. 6, 2012 — ADVOCIN ™ (danofloxacin mesylate) is now available from Pfizer Animal Health — offering a cost - effective fluoroquinolone alternative for the treatment of bovine respiratory disease (BRD). (zoetisus.com)